Our Technology
Unleash the therapeutic potential of active pharmaceutical ingredients previously limited by unfavorable toxicities, in vivo stabilities, and pharmacokinetic profiles; enhance treatment efficacies and transform the target molecule with additional mechanisms of action with Tripartite Therapeutics' proprietary OmniLink® and Polarpeutic® technologies.
OmniLink®
Tripartite Therapeutics' OmniLink® technology can achieve stable conjugation of cytotoxic drugs, immune adjuvants and other small bio- and chemical molecules to antibodies or antibody fragments with minimal premature release of the payloads in systemic circulation, making it possible to create conjugated drugs using exceptionally high potency active moieties that would otherwise be hampered by dose-limiting toxicities. A high ratio of conjugated molecule per antibody (i.e. antibody-drug ration, DAR) further expands the therapeutic index with high level of efficacy achievable. The versatility of the OmniLink® technology even allows for treatment modalities with dual mechanisms of action via dual-payload conjugations, the addition of a second biomarker targeting capability to an antibody drug conjugate, or the harnessing of the body's immune response for cancer immunotherapy. We expect the endless treatment possibilities enabled by the combination of treatment modalities to culminate both first-in-class and best-in-class treatment options in our continuous flow of product pipelines.
Polarpeutic®
The ideal design of antibody drug conjugates (ADCs) is one that exerts highly effective tumor eradication potency with minimal collateral damage to healthy cells. In practice, effectiveness of current ADCs are hindered by dose-limiting toxicities associated with the drug payload. With Polarpeutic® technology, ADC payloads, which are primarily hydrophobic in nature, can be rendered hydrophilic while retaining its pharmacological effects. Polarpeutic® drug payloads allows for ADCs with higher drug-to-antibody (DAR) ratios without rendering the overall ADC hydrophobic, thereby minimizing the risk of aggregation or rapid immune clearance and immune toxicity. When released from the ADC, Polarpeutic® drug payloads are not substrates of cancer multi-drug resistance (MDR) transporters and the hydrophilicity prevents passive transport across the lipid-bilayer of the cellular membrane, making Polarpeutic® drug payloads more effective than current leaders in approved ADC drugs as demonstrated in animal models. The technology has been successfully applied to a wide range of cytotoxic molecules including maytansinoids (DM1, DM4), camptothecin analogues (exatecan, SN38), auristatins (MMAE, MMAF), as well as non-cytotoxic payloads such as toll-like receptor agonists (TLR 7/8) for immuno-oncology. In combination with OmniLink®, we are creating best-in-class drug candidates across different oncology indications for IND-enabling development in 2023 - 2024.